Ligand Pharm (LGND)

$190.11 +1.04 (0.55%)
Market Cap 3.74B
Revenue (ttm) 167.13M
Net Income (ttm) -4.03M
EPS (ttm) N/A
PE Ratio 91.34
Forward PE 36.34
Profit Margin -2.41%
Debt to Equity Ratio 0.00
Volume 205,700
Avg Vol 213,232
Day's Range N/A - N/A
Shares Out 19.68M
Stochastic %K 22%
Beta 0.97
Analysts Strong Sell
Price Target $235.11

Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pn...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 550 7500
Address:
555 Heritage Drive, Suite 200, Jupiter, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 11:54 AM
$LGND RSI: 58.44, MACD: -0.2537 Vol: 5.37, MA20: 191.76, MA50: 195.07 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BinaryLogic
BinaryLogic Dec. 27 at 6:02 PM
$OBIO $MDT $LGND
0 · Reply
CrimsonCrafter
CrimsonCrafter Dec. 27 at 10:07 AM
$LGND Risk tolerance remains selective and tied closely to execution credibility. Governance alignment can reduce perceived uncertainty. Any deterioration in traction could reset expectations abruptly. Execution quality becomes the defining catalyst from here.
0 · Reply
garygb
garygb Dec. 22 at 5:06 PM
$LGND Upward trending
0 · Reply
LilySanders
LilySanders Dec. 20 at 4:08 PM
$LGND biotech royalty play in a range, rerate only really happens if it clears this band on strong volume post catalyst
0 · Reply
SacerTractus
SacerTractus Dec. 16 at 5:46 PM
$LGND biotech licensing play, consolidating mid range where a volume breakout could start a more directional move
0 · Reply
TradeWoFear
TradeWoFear Dec. 16 at 2:58 AM
$LGND Congrats to all who followed since last post!!
0 · Reply
ZacksSCR
ZacksSCR Dec. 15 at 4:05 PM
$LGND: 2025 Analyst Day https://buff.ly/KgoVbOg
0 · Reply
KazienInvestor
KazienInvestor Dec. 14 at 2:21 AM
$LGND legend
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 14 at 2:17 AM
sticking to what works - will buy $LGND when H% gets low like this
0 · Reply
Latest News on LGND
Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

Dec 10, 2025, 3:47 AM EST - 26 days ago

Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Dec 9, 2025, 7:00 AM EST - 26 days ago

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come

Nov 13, 2025, 10:10 AM EST - 7 weeks ago

Ligand Pharmaceuticals: Superb Q3/2025 With Second Guidance Raise Heralds Good Things To Come

Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript

Nov 8, 2025, 4:56 PM EST - 2 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q3 2025 Earnings Call Transcript

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

Nov 6, 2025, 7:00 AM EST - 2 months ago

Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance

Ligand to Participate in November Investor Conferences

Oct 30, 2025, 4:01 PM EDT - 2 months ago

Ligand to Participate in November Investor Conferences

Impax Small Cap Fund Q3 2025 Contributors And Detractors

Oct 28, 2025, 4:26 PM EDT - 2 months ago

Impax Small Cap Fund Q3 2025 Contributors And Detractors

AAMI CIEN HCAT INSP SIBN

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 23, 2025, 7:00 AM EDT - 2 months ago

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

Ligand to Host Investor Day on December 9, 2025

Oct 16, 2025, 7:00 AM EDT - 2 months ago

Ligand to Host Investor Day on December 9, 2025

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Oct 9, 2025, 7:00 AM EDT - 3 months ago

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

Sep 25, 2025, 2:30 AM EDT - 3 months ago

Arecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292

Ligand to Participate in September Investor Conferences

Aug 19, 2025, 4:00 PM EDT - 4 months ago

Ligand to Participate in September Investor Conferences

Ligand Announces Closing of Convertible Senior Notes Offering

Aug 14, 2025, 4:00 PM EDT - 5 months ago

Ligand Announces Closing of Convertible Senior Notes Offering

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

Aug 11, 2025, 11:46 PM EDT - 5 months ago

Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

Aug 11, 2025, 7:00 AM EDT - 5 months ago

Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030

Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:01 PM EDT - 5 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Aug 7, 2025, 7:00 AM EDT - 5 months ago

Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

Jul 31, 2025, 4:01 PM EDT - 5 months ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

MDT OBIO

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 7:00 AM EDT - 5 months ago

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Jul 10, 2025, 8:00 AM EDT - 6 months ago

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Jul 2, 2025, 7:00 AM EDT - 6 months ago

Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Jul 2, 2025, 7:00 AM EDT - 6 months ago

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

Jun 24, 2025, 2:47 PM EDT - 6 months ago

Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward

Ligand Announces 2025 Investor Day in New York City

Jun 11, 2025, 7:00 AM EDT - 7 months ago

Ligand Announces 2025 Investor Day in New York City

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

May 14, 2025, 7:00 AM EDT - 8 months ago

Ligand to Ring the Nasdaq Opening Bell on May 19, 2025

Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:19 PM EDT - 8 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q1 2025 Earnings Call Transcript

Ligand Reports First Quarter 2025 Financial Results

May 8, 2025, 7:00 AM EDT - 8 months ago

Ligand Reports First Quarter 2025 Financial Results

Ligand to Participate in May Investor Conferences

May 1, 2025, 7:00 AM EDT - 8 months ago

Ligand to Participate in May Investor Conferences

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 7:00 AM EDT - 9 months ago

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Apr 17, 2025, 6:00 AM EDT - 9 months ago

Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics

Ligand to Participate in March Investor Conferences

Mar 3, 2025, 7:00 AM EST - 10 months ago

Ligand to Participate in March Investor Conferences

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 3:06 PM EST - 11 months ago

Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call Transcript

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 11 months ago

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Feb 25, 2025, 7:00 AM EST - 11 months ago

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

XOMA

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Feb 13, 2025, 7:00 AM EST - 11 months ago

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 6, 2025, 7:00 AM EST - 11 months ago

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Looking Back On Ligand Pharmaceuticals

Feb 3, 2025, 2:59 PM EST - 11 months ago

Looking Back On Ligand Pharmaceuticals

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

Jan 13, 2025, 6:10 PM EST - 1 year ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Dec 10, 2024, 9:00 AM EST - 1 year ago

Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Nov 24, 2024, 6:50 AM EST - 1 year ago

Ligand Pharmaceuticals: Buy This Strong Growing Pharma And Get A Stake In Dozens Of Therapies

Ligand to Present at Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ligand to Present at Stifel 2024 Healthcare Conference

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 8:07 AM EST - 1 year ago

Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Nov 7, 2024, 7:00 AM EST - 1 year ago

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Nov 1, 2024, 8:01 AM EDT - 1 year ago

Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 23, 2024, 4:01 PM EDT - 1 year ago

Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

Sep 6, 2024, 9:20 AM EDT - 1 year ago

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

TVTX

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Aug 30, 2024, 4:04 AM EDT - 1 year ago

CD40 Ligand Market - Global Monoclonal Antibody, Polyclonal Antibody, Autoimmune Disease Treatment, Immunotherapy, Vaccine Development Forecast 2024-2030

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 20, 2024, 9:00 AM EDT - 1 year ago

Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 10:58 PM EDT - 1 year ago

Ligand Pharmaceuticals Incorporated (LGND) Q2 2024 Earnings Call Transcript

Ligand Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Ligand Reports Second Quarter 2024 Financial Results

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 2 at 11:54 AM
$LGND RSI: 58.44, MACD: -0.2537 Vol: 5.37, MA20: 191.76, MA50: 195.07 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BinaryLogic
BinaryLogic Dec. 27 at 6:02 PM
$OBIO $MDT $LGND
0 · Reply
CrimsonCrafter
CrimsonCrafter Dec. 27 at 10:07 AM
$LGND Risk tolerance remains selective and tied closely to execution credibility. Governance alignment can reduce perceived uncertainty. Any deterioration in traction could reset expectations abruptly. Execution quality becomes the defining catalyst from here.
0 · Reply
garygb
garygb Dec. 22 at 5:06 PM
$LGND Upward trending
0 · Reply
LilySanders
LilySanders Dec. 20 at 4:08 PM
$LGND biotech royalty play in a range, rerate only really happens if it clears this band on strong volume post catalyst
0 · Reply
SacerTractus
SacerTractus Dec. 16 at 5:46 PM
$LGND biotech licensing play, consolidating mid range where a volume breakout could start a more directional move
0 · Reply
TradeWoFear
TradeWoFear Dec. 16 at 2:58 AM
$LGND Congrats to all who followed since last post!!
0 · Reply
ZacksSCR
ZacksSCR Dec. 15 at 4:05 PM
$LGND: 2025 Analyst Day https://buff.ly/KgoVbOg
0 · Reply
KazienInvestor
KazienInvestor Dec. 14 at 2:21 AM
$LGND legend
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 14 at 2:17 AM
sticking to what works - will buy $LGND when H% gets low like this
0 · Reply
mikesterz7
mikesterz7 Dec. 14 at 1:25 AM
$LGND Norges Bank Acquires Shares of 14,073 Ligand Pharmaceuticals Incorporated
0 · Reply
Letthegamesbegin
Letthegamesbegin Dec. 14 at 1:08 AM
$LGND $RIGL Not sure why there is such enthusiasm here over stock price when fundamentally they are overvalued. Check out $RIGL for a better valuation.
1 · Reply
TradeWoFear
TradeWoFear Dec. 14 at 1:00 AM
$LGND Very interesting !! Forecasted by CNN!!! i will leave the guess to you!!!
0 · Reply
JFDI
JFDI Dec. 13 at 11:50 PM
$LGND
0 · Reply
Doozio
Doozio Dec. 13 at 10:53 PM
Sum wud say whut happens NXT may even be $LGND ary! 🐒🍌🧠⏰♾️
0 · Reply
BinaryLogic
BinaryLogic Dec. 11 at 2:22 AM
$OBIO [Again] Partnerships with $MDT and $LGND, 137 global patents, breakthrough device designation, Cash runway to 1H-2027 with $95M Cash/ST against $61M Total Liabilities. Avg PT: $13.8 and currently trading at $4.75. TD Cowen just provided its forecast (PT) at $15. https://www.stocktitan.net/news/OBIO/orchestra-bio-med-announces-avim-therapy-and-virtue-sab-program-7359wz18v149.html
0 · Reply
IN0V8
IN0V8 Dec. 10 at 4:29 PM
$LGND Buy Stifel raises target price to $230 from $220
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 2:26 PM
RBC Capital has adjusted their stance on Ligand Pharmaceuticals ( $LGND ), setting the rating to Outperform with a target price of 234 → 235.
0 · Reply
JarvisFlow
JarvisFlow Dec. 10 at 1:05 PM
Stifel has updated their rating for Ligand Pharmaceuticals ( $LGND ) to Buy with a price target of 230.
0 · Reply
JarvisFlow
JarvisFlow Dec. 9 at 7:37 PM
Citigroup has adjusted their stance on Ligand Pharmaceuticals ( $LGND ), setting the rating to Buy with a target price of 270.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 9 at 5:54 PM
$LGND
0 · Reply
tyogs
tyogs Dec. 1 at 6:55 PM
$LGND possible bounce off the high 180s then retest 200 bucks. Could shoot higher from there or reject until next earnings.
0 · Reply